指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

印度东北部血流感染万古霉素耐药肠球菌的分子分型:ERIC-PCR前瞻性横断面研究

Molecular profiling of vancomycin-resistant enterococci isolated from bloodstream infections by enterobacterial repetitive intergenic consensus-polymerase chain reaction: A prospective cross-sectional study from Northeast India.
指南 / 共识 · Indian J Med Microbiol · 2025-07-07
一句话结论印度东北部三级医院血流感染肠球菌中VRE占24.6%,均携带VanA基因,ERIC-PCR以Cluster III为主(11株),利奈唑胺敏感性100%。

该研究为印度特里普拉邦三级医院2021年8月至2024年12月的前瞻性横断面研究,分析626份血培养标本。263份(42%)培养阳性,肠球菌为第三常见分离菌(21.7%),以粪肠球菌为主(63.2%)。利奈唑胺敏感性100%,万古霉素敏感性75.4%,环丙沙星敏感性最低(44%)。VRE检出14株(24.6%),全部携带VanA基因;ERIC-PCR分3簇,Cluster III含11株(包括ATCC对照株)。作者认为VanA介导耐药在重症监护环境中的聚集需立即加强感染控制和针对性抗菌策略。

要点

  • 626份血培养中263份(42%)阳性,肠球菌占21.7%,为第三常见分离菌,以粪肠球菌为主(63.2%)。
  • VRE检出14株(24.6%),全部携带VanA基因,ERIC-PCR分3簇,Cluster III含11株(包括ATCC对照株)。
  • 利奈唑胺敏感性100%,万古霉素敏感性75.4%,环丙沙星敏感性最低(44%)。
  • 病例主要来自ICU(52.6%)和内科(49.1%),提示重症监护环境为VRE聚集重点区域。
  • 作者认为VanA介导耐药在危重症环境的聚集需立即关注感染控制与针对性抗菌策略。

适用人群与场景

  • 印度特里普拉邦三级医院成人及儿科患者,送检血培养标本者。
  • 研究场景为医院内血流感染,病例主要来自ICU(52.6%)和内科(49.1%)。

研究设计与关键结果

  • 研究类型为医院内前瞻性横断面研究,2021年8月至2024年12月在印度东北部特里普拉邦三级医院进行,共分析626份血培养标本。
  • 263份(42%)血培养阳性,肠球菌为第三常见分离菌(21.7%),以粪肠球菌为主(63.2%)。
  • 药敏结果显示利奈唑胺敏感性100%,万古霉素敏感性75.4%,环丙沙星敏感性44%(耐药率最高)。
  • VRE检出14株(24.6%),全部携带VanA基因;ERIC-PCR分3簇,Cluster III含11株(包括ATCC对照株)。

证据类型、等级与局限

  • 证据类型:前瞻性横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为VanA介导的万古霉素耐药在重症监护环境中的聚集需立即关注感染控制措施和针对性抗菌策略。
  • 作者建议未来研究应聚焦于该地区医院及社区环境中VRE传播的环境与流行病学因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Enterococcus spp. Has emerged as a significant cause of bacteremia, often leading to severe complications such as Infective Endocarditis. The rise of Vancomycin-Resistant Enterococci (VRE) poses a critical challenge in treating Enterococcal bacteremia, particularly in hospital settings. This study aims to conduct molecular characterization and genotyping of VRE strains isolated from blood samples in a tertiary care hospital.

METHODS: This hospital-based prospective cross-sectional study was conducted at a tertiary care hospital in Tripura, Northeast India, from August 2021 to December 2024. Blood samples from both adult and pediatric patients were collected and processed for culture and organism identification following departmental protocols. Antimicrobial susceptibility of isolated Enterococcus spp. Was assessed, and vancomycin resistance confirmed through VRE screening. Real-time PCR was employed for VRE gene detection, and ERIC-PCR was used for genotyping the VRE strains.

RESULTS: During the study, 626 blood samples were analyzed, with 263 (42 %) testing positive for pathogens. Enterococcus spp. Was the third most common isolate (21.7 %), predominantly E. faecalis (63.2 %). Most cases originated from ICU (52.6 %) and the Medicine Department (49.1 %). Linezolid showed 100 % sensitivity, while Vancomycin had 75.4 % sensitivity. Ciprofloxacin exhibited the highest resistance (44 % sensitivity). VRE was detected in 14 strains (24.6 %), all carrying the VanA gene. ERIC-PCR identified three clusters, with most isolates (n=11) in Cluster III, including the ATCC control strain.

CONCLUSION: This study highlighted the prevalence, resistance patterns, and molecular characteristics of Enterococcus spp. Causing bloodstream infections in a Northeast Indian state. The predominance of VanA-mediated resistance and its clustering in critical care settings call for immediate attention to infection control and targeted antimicrobial strategies. Future research should focus on the environmental and epidemiological factors contributing to the spread of VRE in hospital as well as community settings in the region.

来源:Indian J Med Microbiol,查看原文。版权归原作者所有。

参考来源

  1. Chakrabarti A, Bhattacharya S, Pratap Datta R, et al. Molecular profiling of vancomycin-resistant enterococci isolated from bloodstream infections by enterobacterial repetitive intergenic consensus-polymerase chain reaction: A prospective cross-sectional study from Northeast India. Indian J Med Microbiol. 2025. PMID: 40633733. doi:10.1016/j.ijmmb.2025.100914

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。